Insider Trading Alert - OPK, IPXL And MA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 12, 2014, 136 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.01 to $1,795,652,303.10.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 60,900 shares at $9.12 on March 12, 2014. Following this transaction, the CEO & Chairman owned 139.5 million shares meaning that the stake was reduced by 0.04% with the 60,900-share transaction.

The shares most recently traded at $9.24, up $0.12, or 1.27% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.7 billion and is part of the health care sector and health services industry. Shares are up 6.52% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Impax Laboratories (IPXL) - FREE Research Report

Markbreiter Michael who is Director at Impax Laboratories sold 4,000 shares at $27.54 on March 12, 2014. Following this transaction, the Director owned 9,699 shares meaning that the stake was reduced by 29.2% with the 4,000-share transaction.

The shares most recently traded at $27.59, up $0.05, or 0.18% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 6,000

The average volume for Impax Laboratories has been 534,500 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 8.47% year-to-date as of the close of trading on Friday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 18.6. Currently there are 3 analysts that rate Impax Laboratories a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and feeble growth in the company's earnings per share. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MasterCard Incorporated (MA) - FREE Research Report

McWilton Chris who is President, North America at MasterCard Incorporated sold 17,269 shares at $77.57 on March 12, 2014. Following this transaction, the President, North America owned 41,050 shares meaning that the stake was reduced by 29.61% with the 17,269-share transaction.

Flood Gary J who is President, Gl Prod & Solutions at MasterCard Incorporated sold 9,298 shares at $77.49 on March 12, 2014. Following this transaction, the President, Gl Prod & Solutions owned 63,078 shares meaning that the stake was reduced by 12.85% with the 9,298-share transaction.

The shares most recently traded at $77.39, down $0.10, or 0.13% since the insider transaction. Historical insider transactions for MasterCard Incorporated go as follows:

  • 4-Week # shares sold: 404,800
  • 12-Week # shares sold: 2.5 million
  • 24-Week # shares sold: 2.5 million

The average volume for MasterCard Incorporated has been 8.1 million shares per day over the past 30 days. MasterCard Incorporated has a market cap of $88.6 billion and is part of the financial sector and financial services industry. Shares are down 7.08% year-to-date as of the close of trading on Friday.

MasterCard Incorporated provides transaction processing and other payment-related services in the United States and internationally. It facilitates the processing of payment transactions, including authorization, clearing, and settlement, as well as delivers related products and services. The stock currently has a dividend yield of 0.57%. The company has a P/E ratio of 29.6. Currently there are 17 analysts that rate MasterCard Incorporated a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MA - FREE

TheStreet Quant Ratings rates MasterCard Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full MasterCard Incorporated Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Biotech Movers: Paratek, Opko, Endo

Biotech Movers: Paratek, Opko, Endo